
Oncology NEWS International
- Oncology NEWS International Vol 17 No 7
- Volume 17
- Issue 7
ThromboGenics and BioInvent Announce Alliance with Roche
UVEN, Belgium-ThromboGenics NV and BioInvent International AB (Lund, Sweden) have entered into a license agreement with Roche for their jointly developed anticancer agent TB-403, a novel monoclonal antibody that blocks PIGF, one of the growth factors responsible for angiogenesis.
UVEN, Belgium-ThromboGenics NV and BioInvent International AB (Lund, Sweden) have entered into a license agreement with Roche for their jointly developed anticancer agent TB-403, a novel monoclonal antibody that blocks PIGF, one of the growth factors responsible for angiogenesis.
Articles in this issue
almost 18 years ago
National Cancer Survivors Dayalmost 18 years ago
New Indication for Velcade in Previously Untreated Myelomaalmost 18 years ago
Risk Factors for Mantle Cell Lymphoma Identifiedalmost 18 years ago
RAS Mutations Enhance Chemotherapy in AMLalmost 18 years ago
Antidiabetic Agent Metformin May Boost pCRs in Breast Caalmost 18 years ago
Eisai Seeks Full FDA Approval for Ontak for CTCLalmost 18 years ago
Symptom Screen Plus CA125 Detects Early Ovarian Caalmost 18 years ago
Cisplatin Linked to Cardiac Complications in Testicular Ca Patientsalmost 18 years ago
Updated X-ACT Study Results Presentedalmost 18 years ago
Gene Signature Identifies Low-Risk Patients in MAGE-A3 TrialNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Related Content



















































